secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039759
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M
--------------------------------------------------------------------------------

- Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.
- Net loss $24.0M ($0.50 EPS) vs $24.8M loss in Q2 2022; cash and investments $137.2M as of June 30.
- FY 2023 revenue guidance tightened to $70M-$72M; net loss expected ~$103M, cash usage ~$70M.
- VA MVP exercised first of four one-year renewal options; second patent lawsuit filed against Foresight Diagnostics.
- Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical for rectal cancer biomarker analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/0000950170-23-039759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/psnl-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer